Glycoprotein Asporin Is Up-regulated By Three-dimensional Growth And Promotes Invasion Of Breast Cancer Cells | 48560
Journal of Clinical & Experimental Pathology
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Asporin belongs to small leucine rich proteoglycans family and its crucial characteristic is ability to bind collagens and initiate
their mineralization. Asporin plays important role in normal development, in particular of cartilage, bone and teeth. Although
asporin can now be found in multiple cancer related studies, its role in breast cancer is not clear. We have performed in silico search
and found; Hs578T breast cancer cell line with asporin expression which we confirmed by quantitative RT-PCR and western blotting.
Human dental pulp stem cells were used for validation of asporin antibodies. Out of multiple testing, we found that asporin can be
down regulated by bone morphogenetic protein 4 (BMP4) while up-regulation may be facilitated by serum-free cultivation or by
three dimensional growth in stiff Alvetex scaffold. Down regulation by shRNA inhibited invasion of Hs578T through collagen type I
matrix while adhesion and spheroid growth were not affected. Invasion of asporin-negative MDA-MB-231 and BT549 breast cancer
cells through collagen type I was enhanced by recombinant asporin. In line with other studies, we have confirmed aspirin expression
by RNA scope in situ hybridization in cancer associated fibroblasts in invasive breast cancer. We have not found any reliable antibody
for immunohistochemistry. In conclusion, asporin expression may be regulated by different stimuli from tumor microenvironment,
such as 3D culture, starvation or BMP4, which may in turn modulate extracellular matrix and invasion of breast cancer.
Jan Bouchal has graduated as Molecular Biologist from Masaryk University in Brno and completed his PhD from Palacky University in Olomouc, Czech Republic. He pursued his Postdoctoral training at Innsbruck Medical University in Austria and other research institutes in Denmark, United Kingdom and Norway. He has published more than 40 papers in reputed journals, mostly on breast and prostate cancer.